Anchored in three decades of pioneering academic research by its three scientific founders associated to Harvard/Massachusetts General Hospital; Cincinnati Childrens Research Foundation; and Instituto Nacional de Ciencias Medicas y NutricionMexico, Glycosyn, Inc. is a biotechnology therapeutics and diagnostics company, focused to reducing or eliminating infant and childhood diarrhea worldwide, the primary cause of morbidity and mortality among children. In addition, Glycosyn is developing products for travelers diarrhea and animal health, as well as diagnostics and therapeutics targeting necrotizing enterocolitis and other conditions. The early work discovered natural, anti-infective components (glycans) in human breast milk and demonstrated that these components provide significant protection against infectious diarrhea. Human milk contains thousands of bioactive glycan structures with specific functions that promote health. Specific human milk glycans have been found to be anti-infective, anti-inflammatory, and/or to promote mucosal development and immunity. Glycosyn scientists has identified specific glycans unique to human milk that have translational potential as novel therapeutic agents to promote healthy development and reduce risk of infection, inflammatory diseases, and adiposity. Glycosyn has licensed intellectual property protecting these discoveries and inventions, and is in the process of developing methods for large-scale economic production of anti-infective glycans. Proven safe and effective and, unlike antibiotics, will not promote the development of pathogen resistance, this new class of products promises to impact significantly the important public health problem: infant and childhood diarrhea. Glycosyn has partnered with Grameen Bank and Professor Muhammad Yunus, 2006 Nobel Peace Prize winner, to distribute these products to children with the greatest need, initially in Bangladesh. Professor Yunus also serves on the Glycosyn Advisory Board
